Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. More Details
Flawless balance sheet with poor track record.
Share Price & News
How has Instem's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INS is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: INS's weekly volatility (2%) has been stable over the past year.
7 Day Return
GB Healthcare Services
1 Year Return
GB Healthcare Services
Return vs Industry: INS exceeded the UK Healthcare Services industry which returned 2.4% over the past year.
Return vs Market: INS exceeded the UK Market which returned -6.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Instem's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StInstem plc (LON:INS) Insiders Have Been Selling
1 month ago | Simply Wall StDeclining Stock and Decent Financials: Is The Market Wrong About Instem plc (LON:INS)?
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of Instem plc (LON:INS)?
Is Instem undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: INS (£4.65) is trading above our estimate of fair value (£3.8)
Significantly Below Fair Value: INS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INS is poor value based on its PE Ratio (226.4x) compared to the XE Healthcare Services industry average (46.3x).
PE vs Market: INS is poor value based on its PE Ratio (226.4x) compared to the UK market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INS is overvalued based on its PB Ratio (5.7x) compared to the GB Healthcare Services industry average (4.4x).
How is Instem forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INS's forecast earnings growth is above the savings rate (1.2%).
Earnings vs Market: Insufficient data to determine if INS's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INS's revenue (6.2% per year) is forecast to grow slower than the UK market (6.8% per year).
High Growth Revenue: INS's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INS's Return on Equity is forecast to be low in 3 years time (6.4%).
How has Instem performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INS has a large one-off loss of £3.4M impacting its June 30 2020 financial results.
Growing Profit Margin: INS's current net profit margins (1.2%) are lower than last year (7.3%).
Past Earnings Growth Analysis
Earnings Trend: INS's earnings have grown by 12.6% per year over the past 5 years.
Accelerating Growth: INS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INS had negative earnings growth (-80.6%) over the past year, making it difficult to compare to the Healthcare Services industry average (-14.6%).
Return on Equity
High ROE: INS's Return on Equity (2%) is considered low.
How is Instem's financial position?
Financial Position Analysis
Short Term Liabilities: INS's short term assets (£18.4M) exceed its short term liabilities (£15.0M).
Long Term Liabilities: INS's short term assets (£18.4M) exceed its long term liabilities (£7.2M).
Debt to Equity History and Analysis
Debt Level: INS is debt free.
Reducing Debt: INS has no debt compared to 5 years ago when its debt to equity ratio was 30.6%.
Debt Coverage: INS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INS has no debt, therefore coverage of interest payments is not a concern.
What is Instem current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INS's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Phil Reason (58 yo)
Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who ...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD348.22K) is about average for companies of similar size in the UK market ($USD347.05K).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||no data||UK£261.00k||3.57% |
|CFO, Secretary & Executive Director||9.08yrs||UK£141.00k||no data|
|Chief Operating Officer||3.92yrs||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Vice President of Global Marketing||no data||no data||no data|
|Senior Vice President of Global Sales||4.33yrs||no data||no data|
|Vice President of Corporate Development||no data||no data||no data|
|Head of People Services||1.92yrs||no data||no data|
|Executive Vice President of Regulatory eStudy Solutions||no data||no data||no data|
|Executive Vice President of Preclinical Solutions||no data||no data||no data|
Experienced Management: INS's management team is considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.
Instem plc's company bio, employee growth, exchange listings and data sources
- Name: Instem plc
- Ticker: INS
- Exchange: AIM
- Founded: 1969
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£95.241m
- Shares outstanding: 20.48m
- Website: https://www.instem.com
Number of Employees
- Instem plc
- Diamond Way
- Stone Business Park
- ST15 0SD
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INS||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Oct 2010|
|54I||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Oct 2010|
Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 20:06|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.